Evaluation of incidental testicular dose with thermoluminescence dosimetry during prostate radiotherapy


      The aim of this study was to investigate incidental testicular doses during intensity modulated radiation therapy (IMRT) in patients treated with prostate radiotherapy only (PORT) and whole pelvis radiotherapy (WPRT). A total of 34 prostate cancer patients with intermediate and high risk were included in this prospective study. Each patient in the intermediate risk group received a total of 78 Gy in 39 fractions for prostate and seminal vesicles. In patients in the high risk group, 2 Gy daily fraction dose for pelvic lymphatics was given to 50 Gy, and then 78 Gy was given to prostate and seminal vesicles volumes. Treatment plans were created for all patients using the IMRT technique with 6MV. Testicular doses were measured for WPRT and PORT by thermoluminescence dosimetry (TLD) detectors placed on testis surface. Testicular doses measured for WPRT and PORT were compared. The isocenter to testicular distance for WPRT and PORT was 16.83-cm (13.20 to 18.80-cm) and 11.15 cm (9.10 to 13.00-cm), respectively. The mean testicular dose measurements of TPS and TLD per fraction during PORT were 2.41 cGy (1.95 to 3.60 cGy) and 3.70 cGy (2.80 to 5.10 cGy), respectively (p = 0.00). In WPRT irradiation, mean testicular dose values of TPS and TLD per fraction were measured as 3.85 cGy (2.00 to 5.70 cGy) and 5.85 cGy (4.25 to 7.55 cGy), respectively (p = 0.00). The cumulative mean scattered dose for PORT irradiation of 78 Gy in 39 fractions was 144.30 cGy. The mean cumulative dose received by the testis for the high-risk prostate patient was 228.15 cGy. There was a significant difference in testicular dose between WPRT and PORT irradiation. Testicular doses decreased significantly with increasing isocenter-testis distance. Incidental testicular dose during prostate radiotherapy can be significantly detrimental to spermatogenesis. Therefore, the testicles should be contoured as an organ at risk for the estimation of absorbed doses. The use of in vivo dosimetry is recommended for accurate measurement of testicular dose in radiotherapy of prostate cancer for men desiring continued fertility.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Medical Dosimetry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Farhood B
        • Geraily G
        • Alizadeh A
        Incidence and mortality of various cancers in Iran and compare to other countries: A review article.
        Iranian Journal of Public Health. 2018; 47: 309
        • Aras S
        • Tanzer IO
        • Sayır N
        • et al.
        "Radiobiological comparison of flattening filter (FF) and flattening filter-free (FFF) beam in rat laryngeal tissue.".
        International Journal of Radiation Biology. 2021; 97.2: 249-255
        • McLaughlin PW
        • Liss AL
        • Nguyen PL
        • et al.
        ACR appropriateness criteria(R) locally advanced, high-risk prostate cancer.
        Am J Clin Oncol. 2017; 40: 1-10
        • Bagheri H.
        • Rabie Mahdavi S.
        • Shekarchi B.
        • et al.
        Measurement of the contralateral breast photon and thermal neutron doses in breast cancer radiotherapy: A comparison between physical and dynamic wedges.
        Radiation Protection Dosimetry. 2018; 178: 73-81
        • Dearnaley DP
        • Sydes MR
        • Graham JD
        • et al.
        Escalated-dose versus standard- dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial.
        Lancet. Oncol. 2007; 8: 475-487
        • Podder TK
        • Fredman ET
        • Ellis RJ.
        Advances in Radiotherapy for Prostate Cancer Treatment.
        Adv Exp Med Biol. 2019; 1126: 31-47
      1. Banaee, N; Nedaie, HA; Esmati, E; et al. Dose measurement outside of radiotherapy treatment field (Peripheral dose) using thermoluminesent dosimeters. (2014): 355-359.

        • Nicholas S.
        • Chen L.
        • Choflet A.
        • et al.
        Pelvic radiation and normal tissue toxicity.
        Seminars in Radiation Oncology. 2017; 27: 358-369
        • Deng J
        • Chen Z
        • Yu JB
        • et al.
        Testicular doses in image-guided radiotherapy of prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82 (doi:): e39-e47 p.2011.01.071
        • Buchli C
        • Martling A
        • Arver S
        • et al.
        Testicular function after radiotherapy for rectal cancer–a review.
        J Sex Med. 2011; 8: 3220-3226
        • Farhood B
        • Mortezaee K
        • Haghi-Aminjan H
        • et al.
        A systematic review of radiation-induced testicular toxicities following radiotherapy for prostate cancer.
        J Cell Physiol. 2019; (Epub ahead of print. PMID: 30740683)
        • Martin JM
        • Handorf EA
        • Price RA
        • et al.
        Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer.
        Med Dosim. 2015; 40: 186-189
      2. Harman, SM; Metter, EJ; Tobin, JD; et al. Baltimore Longitudinal Study of A (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731.

        • Bakkal BH
        • Vural T
        • Elmas O
        • et al.
        Effect of treatment position and radiotherapy planning on testicular dose in patients with rectal carcinoma.
        J Cancer Res Ther. 2014; 10: 558-562
        • Onal C
        • Bozca R
        • Dolek Y
        • et al.
        Incidental testicular doses during volumetric-modulated ARC radiotherapy in prostate cancer patients.
        Radiotherapy and Oncology. 2020; 152 (S734-S)
        • Budgell GJ
        • Cowan RA
        • Hounsell AR.
        Prediction of scattered dose to the testes in abdominopelvic radiotherapy.
        Clin Oncol-Uk. 2001; 13: 120-125
        • Boehmer D
        • Badakhshi H
        • Kuschke W
        • et al.
        Testicular dose in prostate cancer radiotherapy - Impact on impairment of fertility and hormonal function.
        Strahlenther Onkol. 2005; 181: 179-184
        • King CR
        • Maxim PG
        • Hsu A
        • et al.
        Incidental Testicular Irradiation from Prostate Imrt: It All Adds Up.
        Int J Radiat Oncol. 2010; 77: 484-489
        • Hennies S
        • Wolff HA
        • Jung K
        • et al.
        Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer. Influence on hormone levels, quality of life, and sexual functioning.
        Strahlenther Onkol. 2012; 188: 926-932
        • Haddad P
        • Karimi-Moghaddam Z
        • Esfahani M
        • et al.
        Thermoluminescence dosimetry of the dose received by scrotum and testes in radiotherapy of rectal cancer, compared to the point doses calculated by 3D-planning software.
        Phys Medica. 2018; 45: 143-145